Filing Details
- Accession Number:
- 0001061983-21-000247
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-02 17:16:43
- Reporting Period:
- 2021-11-01
- Accepted Time:
- 2021-11-02 17:16:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1061983 | Cytokinetics Inc | CYTK | Pharmaceutical Preparations (2834) | 943291317 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1316459 | David Cragg | 280 East Grand Avenue South San Francisco CA 94080 | Chief Hr & Admin Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-11-01 | 6,675 | $6.00 | 145,379 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-01 | 6,675 | $34.89 | 138,704 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-11-01 | 18,325 | $6.00 | 157,029 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-01 | 18,325 | $34.89 | 138,704 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Incentive Stock Option (right to buy) | Disposition | 2021-11-01 | 18,325 | $0.00 | 18,325 | $6.00 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-11-01 | 6,675 | $0.00 | 6,675 | $6.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2013-04-05 | 2023-03-05 | No | 4 | M | Direct |
| 0 | 2013-04-05 | 2023-03-05 | No | 4 | M | Direct |
Footnotes
- Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total.
- Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.
- Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.
Billionaire Hedge Funds
